Instructor in Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Geoffrey R. Oxnard, MD
|
|
Give Review
Geoffrey R. Oxnard practices Oncology. He went to medical school at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine has a rank of 10 in research and a 19 in primary care Geoffrey Oxnard is a published doctor and has 36 publications published. The lastest was: 'Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.' Geoffrey Oxnard accepts Medicare payments and is listed with Medicare.gov.
Publications
- Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
- Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
- Enhanced Ratio of Signals Enables Digital Mutation Scanning for Rare Allele Detection.
- Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung Cancer: a multicentre, open-label, phase 2 trial.
- Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic Lung adenocarcinomas.
- Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer.
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA.
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer.
- Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the Lung.
- Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
- Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes.
- New targetable oncogenes in non-small-cell lung Cancer.
- Unsuspected pulmonary embolism in lung Cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism.
- Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung Cancer.
- Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of Lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma.
- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung Cancer.
- Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung Cancer and acquired resistance to erlotinib or gefitinib.
- New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer.
- Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung Cancer recurring after adjuvant erlotinib or gefitinib.
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling.
- Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes.
- Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung Cancer: distinct natural history of patients with tumors harboring the T790M mutation.
- Rebiopsy of lung Cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.
- A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.
- Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
- Early changes in tumor size in patients treated for advanced stage nonsmall cell lung Cancer do not correlate with survival.
- Integrating research training into residency: tools of human investigation.
- False-positive rate of posttherapy positron emission tomography in cervical Cancer.
- Non-small cell lung Cancer in octogenarians: treatment practices and preferences.
- Bevacizumab for non-small-cell lung Cancer.
- The radiologic measurement of mesothelioma.
- Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
- Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
- Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Memorial Sloan-Kettering Cancer Center -
Massachusetts General Hospital -
University of Chicago Pritzker School of Medicine
Hospital
-
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1033300157 | |
| NPPES Provider LastName | OXNARD | |
| NPPES Provider FirstName | GEOFFREY | |
| NPPES Provider ZIPCode | 022155418 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 93.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033300157 |
| Last Name Of The Provider | OXNARD |
| First Name Of The Provider | GEOFFREY |
| View All |
Similar Doctors
|
|
Dr. Cesar M. Castro, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey Liu, MD |
|
|
Dr. Matthew J. Frank, MD |
|
|
Dr. Wendy Y. Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leif W. Ellisen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kimmie Ng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacy W. Gray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip C. Amrein, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rebecca A. Miksad, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Omar Eton, MD
This Doctor is OpenDoctor Recommended.
|